Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Common Equity (2016 - 2026)

Nutex Health (NUTX) has disclosed Common Equity for 17 consecutive years, with $442.1 million as the latest value for Q1 2026.

  • For Q1 2026, Common Equity rose 73.17% year-over-year to $442.1 million; the TTM value through Mar 2026 reached $442.1 million, up 73.17%, while the annual FY2025 figure was $423.4 million, 124.6% up from the prior year.
  • Common Equity hit $442.1 million in Q1 2026 for Nutex Health, up from $423.4 million in the prior quarter.
  • Across five years, Common Equity topped out at $556.1 million in Q2 2022 and bottomed at $79.1 million in Q4 2023.
  • Average Common Equity over 5 years is $212.0 million, with a median of $132.5 million recorded in 2022.
  • Year-over-year, Common Equity crashed 80.54% in 2023 and then surged 310.72% in 2025.
  • Nutex Health's Common Equity stood at $120.3 million in 2022, then tumbled by 34.26% to $79.1 million in 2023, then surged by 138.33% to $188.5 million in 2024, then surged by 124.6% to $423.4 million in 2025, then grew by 4.4% to $442.1 million in 2026.
  • According to Business Quant data, Common Equity over the past three periods came in at $442.1 million, $423.4 million, and $317.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.